Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2024
Blue Shield of California slashes cost of world's best selling drug
1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar ...
Posted by Michael Wonder on 07 Dec 2024
US FDA approves Biocon Biologics' Yesintek biosimilar to J&J's Stelara (ustekinumab)
2 December 2024 - Biocon Biologics announced today that the US FDA has approved Yesintek (ustekinumab-kfce), a biosimilar to the ...
Posted by Michael Wonder on 06 Dec 2024
Molnupiravir for the treatment of patients with COVID-19 infection
26 November 2024 - NICE has published further draft guidance on the use of molnupiravir (Lagevrio) in the NHS in ...
Posted by Michael Wonder on 06 Dec 2024
NICE describes how weight loss drug tirzepatide will be rolled out
5 December 2024 - The medication will initially be offered only to those people with the highest clinical needs. ...
Posted by Michael Wonder on 06 Dec 2024
Rigel announces R289 granted fast track designation by the FDA for lower risk myelodysplastic syndrome
2 December 2024 - Rigel Pharmaceuticals today announced that the US FDA has granted fast track designation to R289 for the ...
Posted by Michael Wonder on 06 Dec 2024
FDA grants breakthrough therapy designation to sacituzumab tirumotecan for the treatment of certain patients with previously treated advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations
3 December 2024 - First breakthrough therapy designation for investigational sac-TMT in the US. ...
Posted by Michael Wonder on 06 Dec 2024
Johnson & Johnson seeks US FDA approval for first paediatric indications for Tremfya (guselkumab)
2 December 2024 - Applications filed for Tremfya to treat children with moderate to severe plaque psoriasis and active juvenile psoriatic ...
Posted by Michael Wonder on 06 Dec 2024
Sana Biotechnology announces fast track designation for SC291 in relapsed/refractory systemic lupus erythematosus
2 December 2025 - Enrolling patients in the GLEAM trial for SC291 in B-cell mediated auto-immune diseases, including systemic lupus erythematosus; ...
Posted by Michael Wonder on 06 Dec 2024
Positive CHMP opinion for the extension of indication of Palforzia for the treatment of toddlers with confirmed peanut allergy
2 December 2024 - Stallergenes Greer today announced that the CHMP of the EMA provided a positive opinion for the extension ...
Posted by Michael Wonder on 06 Dec 2024
Esperion announces new drug submissions in Canada for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) treatments to reduce LDL-cholesterol and cardiovascular risk
2 December 2024 - Esperion today announced that it has filed new drug submissions to Health Canada for Nexletol and Nexlizet, ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...
Posted by Michael Wonder on 06 Dec 2024
Agenda for the December 2024 PBAC intracycle meeting
6 December 2024 - The agenda for the December 2024 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 06 Dec 2024
US FDA approves StemCyte biologics license application for Regenecyte cord blood cell therapy product
22 November 2024 - StemCyte announced today that the US FDA has approved the Biologics License Application for its HPC, cord ...
Posted by Michael Wonder on 06 Dec 2024
Jessica Lawrence’s meds cost her family $75k a year because they’re not listed on the PBS
6 November 2024 - Medications that are subsidised for cancer sufferers are critical to Jess Lawrence’s wellbeing, but because the 25-year-old ...
Posted by Michael Wonder on 06 Dec 2024
Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases
5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...
Posted by Michael Wonder on 06 Dec 2024
MHRA approves new diagnostic agent for adult patients showing signs of cognitive impairment for Alzheimer’s disease
27 November 2024 - The MHRA has approved the medicine flortaucipir (Tauvid), given to adults with memory problems so that doctors ...